BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (September 2024)
22 slides from BioHarvest Sciences's investor presentation, September 2024
Slide 1: The Botanical Synthesis Company Investor Presentation
The Botanical Synthesis Company Investor Presentation September 2024 CSE: BHSC | OTCQB: CNVCF
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such stat
Slide 3: Corporate Overview
Corporate Overview BioHarvest Sciences is a biotech innovator & inventor of Botanical Synthesis – a new process to synthesize plant-based molecules – providing the world with consistent, reliable, economically viable & patentable potent molecules for the next generation of therapeutic solutions. • P
Slide 4: Market Opportunity
Market Opportunity BHSC is Addressing Unmet Health & Wellness Needs With Patentable Plant Molecules Produced Consistently & Economically With the Highest Levels of Sustainability NORTH STAR OF BHSC IS TO DEVELOP 10-15 MOLECULES THAT CHANGE THE WORLD OF HEALTH & WELLNESS FOR HUNDREDS OF MILLIONS OF P
Slide 5: Curative & Preventative Applications
Curative & Preventative Applications BHSC is Addressing Unmet Health & Wellness Needs With Patentable Plant Molecules Produced Consistently & Economically With the Highest Levels of Sustainability Curative Preventative Applications: Applications: Infection Ophthalmology Hematology Hepatology Gastroe
Slide 6: Invested $100M Into Proprietary Technology Process
Invested $100M Into Proprietary Technology Process Which Enables Development of Molecules for Next-Gen Therapeutic Solutions Botanical Synthesis allows for the perpetual creation of consistent botanical molecules, requiring the plant only one time, giving BioHarvest the ability to Address Unmet Medi
Slide 7: Turning Plants Into a Scientifically Reliable Source of Patentable Biological Molecules
Turning Plants Into a Scientifically Reliable Source of Patentable Biological Molecules BioHarvest’s Botanical Synthesis Process Botanical Synthesis Offers Significant Provides New Solutions for Pharma to Advantages Address Unmet Medical Needs Plants possess an infinite source of molecules with hist
Slide 8: Growth Engines Powered by Our Botanical Synthesis Process
BHSC has 2 Growth Engines Powered by Our Botanical Synthesis Process PRODUCTS BUSINESS UNIT CDMO SERVICES BUSINESS UNIT • CDMO PROOF OF CONCEPT / MARKET APPLYING BOTANICAL SYNTHESIS AS A CDMO TO VALIDATION DEVELOP: • LEARNED TO EFFICIENTLY MANUFACTURE AT SCALE • SIMPLE & COMPLEX MOLECULES • CASH GEN
Slide 9: Introducing VINIA: Our Flagship Red Grape Cell-Derived Product
Introducing VINIA®: Our Flagship Red Grape Cell-Derived Direct-to-Consumer Nutraceutical Product • VINIA® is BioHarvest’s first commercial product, a proprietary nutraceutical containing the entire matrix of red grape polyphenols, including Piceid Resveratrol • Botanical Synthesis process increases
Slide 10: Products Anchored in Science & Backed by Clinical Trials
Products Anchored in Science & Backed by Clinical Trials Clinical trial published in peer reviewed scientific journals bioharvest.com/clinical-studies *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any d
Slide 11: Scaling Grape Molecule Across New Higher Margin Verticals
Scaling Grape Molecule Across 3 New Higher Margin Verticals in Next 24 Months Testament to BioHarvest’s Ability to Scale and Enter New Markets VINIA VINIA Skincare VINIA Capsules VINIA Hot Beverages Hydration Products Flagship Nutraceutical Launched December 2023 Launching H1-25 Launching H1 2025 Su
Slide 12: Repeating the VINIA Playbook: Olive & Pomegranate Cells
Repeating the VINIA Playbook: Olive & Pomegranate Cells Business Model Can be Easily Replicated Across New Plant Molecules Olive Cell & Pomegranate Cell Molecules to be Launched in H2 2025 & 2026 Respectively • Olives: Providing at least 15X concentrated amounts of Verbascoside concentration vs. a r
Slide 13: Introducing Service Business Unit
Introducing Service Business Unit Applying Botanical Synthesis as a CDMO: Contract Development & Manufacturing Organization BioHarvest Sciences Service Product CDMO Business Unit Business Unit CSE: BHSC | OTCQB: CNVCF 1 3
Slide 14: Introducing CDMO Products & Services
Introducing CDMO Products & Services BioHarvest Sciences Botanical Synthesis CDMO has the Potential to Become an Emerging Force in Plant-based Biologics Development • Newly launched expansion into the contract development & manufacturing organization (CDMO) market, built upon the success of its comm
Slide 15: CDMO Engines for Growth
CDMO ENGINES FOR GROWTH Pharma & Biotech Nutraceuticals Pharma: (a) Over 140 existing Rx small molecules Major Health and utilize plant-based API, KSM, Wellness focus driven or excipients (b) pursuit of by preventative new molecules in clinical Ph1+ medicine and move Biotech: Over 100 biologics away
Slide 16: CDMO Staged Development Process
CDMO Staged Development Process Two Contracts Already Signed with Tier-1 Partners Across Multiple • ContractsVerticals signed with leading Nasdaq-listed pharmaceutical company and a major food ingredients industry player • Platform is resonating with industry: In advanced negotiations with several o
Slide 17: The CDMO Sales Funnel: An Illustrative Case Study
The CDMO Sales Funnel: An Illustrative Case Study Each Ten Projects Have the Potential to Generate $100M+ in Revenue Over 5 Years Continuous Contract CDMO Projects ~15-24 Month Development Cycle Manufacturing Predictable, High-Margin Royalty ~$1.8-2.5M in NRE Revenue per Revenues Project Targeting T
Slide 18: In-House Biotech Manufacturing and R&D Facilities
In-House Biotech Manufacturing and R&D Facilities World Class Biological Production and R&D Team in Israel • BioHarvest is currently producing VINIA in a state-of-the- art biological production facility in the center of Israel • Production facility located in Yavneh, Israel • Corporate and R&D offic
Slide 19: Financial Highlights
Financial Highlights Quarterly • Success of VINIA® Red Grape Cell product line drove FY23 revenues to a Revenue* record of $12.7 million, reflecting an increase of 131% over 2022 $ in Millions • 90% of VINIA.com revenue is generated from recurring subscriptions • 91% of those on subscriptions of 3 m
Slide 20: Management Team with Track Record of Innovation & Commercial Excellence
Management Team with Track Record of Innovation & Commercial Excellence Ilan Sobel Chief Executive Officer Dr. Zaki Rakib 25+ years developing & executing strategic growth Chairman of the Board strategies 30+ years experience developing disruptive technologies Dr. Yochi Hagay Chief Technology Office
Slide 21: Investment Highlights
Investment Highlights • BioHarvest Botanical Synthesis process technology represents a generational opportunity for pharmaceutical and health & wellness markets o Patented technology platform optimizes the production of the phyto-medicinal molecules in plants to develop pharmaceutical and health and
Slide 22: Contact Us
Contact Us Investor Lucas A. Zimmerman Main: (949) 259-4987 Relations MZ North America BHSC@mzgroup.us BioHarvest Sciences (CSE: BHSC | OTCQB: CNVCF) 625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canada www.bioharvest.com 2 2
BioHarvest Sciences — Investor Presentation (September 2024) on 6ix